|
|
Дата |
|---|
| 20:45 |
| 22.10.2026 |
| 21.10.2026 |
| 20.10.2026 |
| 19.10.2026 |
| 16.10.2026 |
| 15.10.2026 |
| 14.10.2026 |
| 13.10.2026 |
| 12.10.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
1.67
|
1.68
|
2.99
|
1.595
|
3.00
|
1.6712
|
|
|
35 160 342.57
|
86 484.00
|
|
4.94
|
4.99
|
4.27
|
3.89
|
4.31
|
3.95
|
|
|
6 716 040.58
|
16 885.00
|
|
4.34
|
4.48
|
3.95
|
3.95
|
4.54
|
4.41
|
|
|
955 915.38
|
3 586.00
|
|
3.76
|
4.00
|
3.80
|
3.78
|
4.0514
|
3.90
|
|
|
259 325.41
|
1 082.00
|
|
3.66
|
4.75
|
3.75
|
3.64
|
4.05
|
3.74
|
|
|
512 935.46
|
1 550.00
|
|
3.69
|
4.13
|
4.19
|
3.73
|
4.19
|
3.78
|
|
|
379 074.51
|
1 408.00
|
|
3.69
|
5.66
|
3.86
|
3.77
|
3.977
|
3.86
|
|
|
266 726.80
|
1 227.00
|
|
3.69
|
5.37
|
3.93
|
3.83
|
4.35
|
3.88
|
|
|
500 501.23
|
2 167.00
|
|
4.02
|
5.66
|
4.44
|
4.03
|
4.63
|
4.04
|
|
|
925 098.46
|
3 757.00
|
|
4.40
|
5.62
|
4.81
|
4.40
|
4.8771
|
4.45
|
|
|
448 385.59
|
1 125.00
|
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Показать все Скрыть